From the Journals

Quadruple Therapy in HFrEF: What Happens Next?

Study finds high mortality and rehospitalization rates despite guideline-recommended treatment among Medicare beneficiaries.

Share

A study published in JAMA Cardiology reveals that only 7.2% of eligible US patients hospitalized for heart failure with reduced ejection fraction (HFrEF) received guideline-recommended quadruple therapy at discharge. Conducted on 20,651 patients aged 65 and older, the research highlighted a high mortality risk, with 19% of patients dying within a year post-discharge and nearly 37% either dying or being readmitted for heart failure. The analysis suggests a significant clinical burden and high healthcare costs, reinforcing the need for improved medication adherence and access.

Original Source(s)

Quadruple Therapy in HFrEF: What Happens Next?

Study finds high mortality and rehospitalization rates despite guideline-recommended treatment among Medicare beneficiaries.

  • by Kathryn Wighton

  • January 29, 2026

  • 3 min

Related Content

Despite Progress, Heart Disease Still Nation's Leading Killer

Recent statistics show some encouraging news in the fight against cardiovascular disease. Following a five-year upward trend that was likely influenced by the COVID-19 pandemic, the number of deaths from heart disease and stroke has declined.

  • by

  • February 4, 2026

  • 7 min
Baptist Health Heart & Vascular Care Named to Becker’s “100 Hospitals and Health Systems With Great Heart Programs | 2025”

Miami Cardiac & Vascular Institute and The Christine E. Lynn Heart & Vascular Institute — has been recognized by Becker’s Hospital Review as one of the nation’s “100 hospitals and health systems with great heart programs | 2025.”

  • by

  • February 3, 2026

  • 1 min
Rethinking Prehabilitation Before Surgery

Researchers compare personalized versus standard prehabilitation and examine functional, immune, and postoperative outcomes before major elective surgery.